Karin Fijnvandraat

List of Publications by Year
in descending order

64 papers	1,740 citations	279798 23 h-index	289244 40 g-index
64 all docs	64 docs citations	64 times ranked	1775 citing authors

#	Article	IF	Citations
1	Randomized Trial of Platelet-Transfusion Thresholds in Neonates. New England Journal of Medicine, 2019, 380, 242-251.	27.0	288
2	Coagulation Activation and Tissue Necrosis in Meningococcal Septic Shock: Severely Reduced Protein C Levels Predict a High Mortality. Thrombosis and Haemostasis, 1995, 73, 015-020.	3.4	162
3	Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. British Journal of Haematology, 1995, 91, 474-476.	2.5	96
4	Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thrombosis and Haemostasis, 2012, 108, 683-692.	3.4	87
5	Diagnosis and management of haemophilia. BMJ, The, 2012, 344, e2707-e2707.	6.0	82
6	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood, 2015, 125, 3006-3013.	1.4	62
7	A Human Alloantibody Interferes With Binding of Factor IXa to the Factor VIII Light Chain. Blood, 1998, 91, 2347-2352.	1.4	57
8	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	2.5	56
9	Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. American Journal of Hematology, 2016, 91, 763-769.	4.1	48
10	Bleeding spectrum in children with moderate or severe von <scp>W</scp>illebrand disease: <scp>R</scp>elevance of pediatricâ€specific bleeding. American Journal of Hematology, 2015, 90, 1142-1148.	4.1	46
11	Extensive Ethnic Variation and Linkage Disequilibrium at the FCGR2/3 Locus: Different Genetic Associations Revealed in Kawasaki Disease. Frontiers in Immunology, 2019, 10, 185.	4.8	43
12	Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood, 2019, 134, 2354-2360.	1.4	41
13	A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica, 2016, 101, 1159-1169.	3.5	39
14	Comorbidities associated with higher von Willebrand factor (<scp>VWF</scp>) levels may explain the ageâ€related increase of <scp>VWF</scp> in von Willebrand disease. British Journal of Haematology, 2018, 182, 93-105.	2.5	39
15	In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI. American Journal of Neuroradiology, 2016, 37, 1727-1732.	2.4	37
16	Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review. Blood Advances, 2017, 1, 1598-1616.	5.2	34
17	Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thrombosis and Haemostasis, 2015, 114, 46-55.	3.4	33
18	To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity. Blood Reviews, 2017, 31, 339-347.	5.7	30

#	Article	IF	Citations
19	Differences between Platelets Derived from Neonatal Cord Blood and Adult Peripheral Blood Assessed by Mass Spectrometry. Journal of Proteome Research, 2017, 16, 3567-3575.	3.7	28
20	Effect of Nâ€acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial. British Journal of Haematology, 2018, 182, 444-448.	2.5	27
21	The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors. Thrombosis and Haemostasis, 2016, 115, 543-550.	3.4	26
22	Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease. British Journal of Haematology, 2016, 172, 274-284.	2.5	25
23	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	3.5	24
24	Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood, 2021, 138, 2853-2873.	1.4	23
25	The â€œOPTI-CLOTâ€•trial. Thrombosis and Haemostasis, 2015, 114, 639-644.	3.4	22
26	Joint status of patients with nonsevere hemophilia A. Journal of Thrombosis and Haemostasis, 2022, 20, 1126-1137.	3.8	17
27	Dynamic prediction of bleeding risk in thrombocytopenic preterm neonates. Haematologica, 2019, 104, 2300-2306.	3.5	16
28	Immunobiology of Inhibitor Development in Hemophilia A. Seminars in Thrombosis and Hemostasis, 2003, 29, 061-068.	2.7	15
29	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. Thrombosis and Haemostasis, 2018, 118, 152-160.	3.4	15
30	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. American Journal of Hematology, 2019, 94, E201-E205.	4.1	15
31	The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210.	3.8	15
32	Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Review of Hematology, 2020, 13, 313-321.	2.2	15
33	Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease. British Journal of Haematology, 2018, 180, 432-442.	2.5	14
34	Identification of genetic biomarkers for alloimmunization in sickle cell disease. British Journal of Haematology, 2019, 186, 887-899.	2.5	14
35	Sports participation and physical activity in patients with von Willebrand disease. Haemophilia, 2019, 25, 101-108.	2.1	14
36	Daily pain in adults with sickle cell diseaseâ€”a different perspective. American Journal of Hematology, 2017, 92, 179-186.	4.1	11

#	Article	IF	Citations
37	Adoption of emicizumab (HemlibraÂ®) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia, 2021, 27, 736-743.	2.1	11
38	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. Thrombosis and Haemostasis, 2018, 118, 1690-1700.	3.4	10
39	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
40	Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?. Seminars in Thrombosis and Hemostasis, 2018, 44, 531-543.	2.7	9
41	Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial. Lancet Haematology,the, 2021, 8, e492-e502.	4.6	9
42	Prophylaxis in children with haemophilia in an evolving treatment landscape. Haemophilia, 2021, 27, 889-896.	2.1	9
43	Treatmentâ€related risk factors for inhibitor development in nonâ€severe hemophilia A after 50 cumulative exposure days: A caseâ€control study. Journal of Thrombosis and Haemostasis, 2021, 19, 2171-2181.	3.8	8
44	Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thrombosis and Haemostasis, 2022, 122, 208-215.	3.4	7
45	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate PÂ®/Humate PÂ® treatment in von Willebrand disease patients. Journal of Thrombosis and Haemostasis, 2020, 18, 295-305.	3.8	6
46	Hemophilia management: Huge impact of a tiny difference. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 377-385.	2.3	6
47	Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. British Journal of Clinical Pharmacology, 2021, 87, 2602-2613.	2.4	6
48	Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease. British Journal of Haematology, 2022, 196, 769-776.	2.5	6
49	SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders. Journal of Thrombosis and Haemostasis, 2022, 20, 2001-2011.	3.8	6
50	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. HemaSphere, 2021, 5, e542.	2.7	5
51	Population pharmacokinetics of the von Willebrand factorâ€“factor VIII interaction in patients with von Willebrand disease. Blood Advances, 2021, 5, 1513-1522.	5.2	5
52	Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a caseâ€'control study. British Journal of Haematology, 2020, 189, 1182-1191.	2.5	3
53	Volume of White Matter Hyperintensities Predicts Neurocognitive Functioning in Children with Sickle Cell Disease. Blood, 2014, 124, 2720-2720.	1.4	2
54	Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease. Blood Advances, 2022, 6, 5317-5326.	5.2	2

#	Article	IF	Citations
55	The factor VIII treatment history of nonâ€severe hemophilia Aâ€"Response from original authors Abdi et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2642-2644.	3.8	1
56	Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. Journal of Clinical and Translational Research, 2018, , .	0.3	1
57	Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. Journal of Clinical and Translational Research, 2018, 3, 351-357.	0.3	1
58	Social participation is reduced in type 3 Von Willebrand disease patients and in patients with a severe bleeding phenotype. Haemophilia, 2022, 28, 278-285.	2.1	1
59	Cognitive functioning in young adult patients with sickle cell disease. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 14-14.	0.0	0
60	Cerebral imaging with 7-Tesla MRI in patients with sickle cell disease: a pilot study. Tijdschrift Voor Kindergeneeskunde, 2013, 81, 76-76.	0.0	0
61	Targeting Clotting Factor VIII Plasma Values in the Perioperative Setting in Hemophilia a: â€œTackling a Moving Targetâ€•(â€œOPTI-CLOTâ€•Studies). Blood, 2014, 124, 5031-5031.	1.4	0
62	Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Doâ€™s and Donâ€™ts after Discrete Choice Experiment Analysis. Blood, 2014, 124, 5038-5038.	1.4	0
63	The Oxygenscan Provides Clinically Relevant Biomarkers for Treatment Efficacy That Are Associated with Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease. Blood, 2019, 134, 2275-2275.	1.4	0
64	Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. Blood, 2020, 136, 15-16.	1.4	0